Rory Riggs

Mr. Riggs is a co-founder and board member of Cibus; CEO & founder of Locus Analytics LLC and Syntax LLC; chairman and co-founder of Royalty Pharma, the largest investor in revenue producing intellectual property (principally royalty interests in marketed and late stage development biopharmaceutical products); and co-founder and board member of Fibrogen. In addition, he is a board member of Intra-Cellular Therapeutics, Inc., Nuredis, GeneNews and eReceivables. He is the former president and board member of Biomatrix, Inc., a NYSE-listed biotechnology company that developed and launched Synvisc®, an injection used to treat knee pain caused by osteoarthritis and a partner in New Ventures, LLC.

Mr. Riggs received an MBA from Columbia University and a Bachelor of Arts from Middlebury College.